Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
| Condition(s) | Atrial Fibrillation |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging. |
| Who can participate | Inclusion Criteria: Participants must meet the following criteria to be enrolled in the trial: * Participants with atrial fibrillation aged 18 to 79 years old, or * Participants aged 40 to 79 years old, at moderate or high risk for CVD as defined by the 10-year risk Atherosclerotic Cardiovascular Disease (ASCVD), a validated risk calculation tool. * Participants who have access to internet/e-mail in their homes. * Participants who have access to a compatible Android mobile device or compatible iOS mobile device (iPhone 4S or newer, iPad 3 or newer). * Participants who are able and willing to return to the study clinic one-year following their baseline CMR for a follow-up appointment and 12-month CMR. * Participants who are able to read, understand, and sign the consent form. Exclusion Crit |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Lead sponsor | Tulane University School of Medicine |
| Locations | New Orleans, Louisiana, United States |
| Start date | 2025-04-08 |
| NCT ID | NCT04703166 |
| Official listing | https://clinicaltrials.gov/study/NCT04703166 |